News
Good News | Wanbangde Pharmaceutical Group's Cefaclor Granules Pass Consistency Evaluation!
Date:
13 Jan,2025
Good News
Wanbande Pharmaceutical Group Co., Ltd.
Cefaclor Granules
Achieve consistency evaluation!
Cefaclor is a beta-lactam antibiotic, classified as a second-generation oral cephalosporin with broad-spectrum antibacterial activity. It exhibits excellent efficacy against both Gram-positive and Gram-negative bacteria. Administered orally, it is rapidly absorbed, boasts high bioavailability, and features a moderately long half-life, effectively maintaining therapeutic drug levels in the bloodstream to ensure optimal treatment outcomes. Cefaclor demonstrates good tolerability and a low incidence of adverse reactions, making it suitable for treating a wide range of infectious diseases—particularly advantageous for patients requiring prolonged medication regimens. Cefaclor granules release the active drug quickly after ingestion, enabling rapid attainment of therapeutic concentrations, which is ideal for managing acute infections. Additionally, the granule formulation is especially well-suited for children and patients who have difficulty swallowing tablets or capsules, enhancing both convenience and adherence to treatment.
In China, the cefaclor market is showing rapid growth, with the market size posting an average annual growth rate of over 15% in the past five years. According to data from Menet, cefaclor sales reached 1.62 billion yuan in 2024. The market is expected to maintain steady growth momentum in 2024 and beyond.
This approval not only highlights Wanbangde Pharmaceutical Group's strong R&D capabilities but also serves as a robust assurance of patient medication safety and treatment efficacy. Additionally, it will pave the way for the product's future market expansion and sales growth. The company will accelerate the marketing efforts for Cefaclor Granules, contributing to the vibrant development of China's pharmaceutical and healthcare industry.
Related Recommendations